Not Yet RecruitingNot Applicable

Coblation Versus Bipolar Diathermy in Management of Refractory Idiopathic Recurrent Anterior Epistaxis in Children.

64 participantsStarted 2025-03-01

Plain-language summary

The aim of this study is to compare the outcomes of coblation technique versus bipolar technique in management of RAE in children regarding the following: 1. Efficacy of each method to stop bleeding. 2. Technical feasibility. 3. Mucosal healing and crust formation. 4. Post operative complications like: synechia formation and septal perforation. 5. Nostril stenosis/ atresia.

Who can participate

Age range6 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. A history of repeated unilateral epistaxis with at least four episodes, at least one episode per week during the preceding 4 weeks.
✓. Age \> 5 years of age and \< 18 years of age.
✓. Failure of topical treatment with an antiseptic ointment, with or without silver nitrate cautery.
✓. A Katsanis epistaxis scoring system (ESS) score of 7-10.
✓. Bleeding originating from Kiesselbach's plexus, located in the anteroinferior portion of the nasal septum.

Exclusion criteria

✕. Patients \< 5 years of age and \>= 18 years of age.
✕. Patients with bilateral epistaxis.
✕. Patients with bleeding tendencies like: Hemophilia, Leukemia, Idiopathic thrombocytopenic purpura, Von Willebrand disease and Thrombasthenia.
✕. Patients with previous nasal surgeries.
✕. Patients with hereditary hemorrhagic telangiectasia.
✕. Patients with vascular lesions like: angiofibroma, pyogenic granuloma and bleeding polypus.
✕. Patients who are unfit for surgery.

What they're measuring

Number of participants with successful hemostasis on the day of the procedure.

Timeframe: The first 24 hours postoperative

Trial details

NCT IDNCT06651840

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

Contact for this trial

Abanoub H Mejalli

01288547168 abanobhosni@gmail.com

View on ClinicalTrials.gov More Epistaxis Nosebleed trials